Methanimine derivative (BN3) alleviates obesity-associated neurobehavior alteration by influencing metabolic and neuroinflammatory gene pathways in in-vivo zebrafish model

Key Points

• BN3 treatment significantly improves neurobehavioral outcomes in zebrafish models of obesity.
• The intervention effectively influences both metabolic pathways and neuroinflammatory gene pathways.
• Assessment using in-vivo zebrafish model explores the effects of BN3 on obesity-related changes.
• Further research may clarify the potential therapeutic roles of BN3 in treating obesity-related neurobehavioral issues.